ECCO 2024
Are all JAKies the same?
high5immunology.tv | IBD | ECCO 2024
PIZZICATO
ECCO 2024
Are all JAKies the same?
ENEIDA registry of GETECCU
ECCO 2024
The quest for predictive markers goes on...
True North
ECCO 2024
S1P-Modulators from a safety perspective
ECCO 2024
Real-world data from a H2H-study on Vedolizumab vs.…
International PSC Registry (IPSCR)
ECCO 2024
Primary sclerosing cholangitis – lessons from a large…
PROFILE
ECCO 2024
A spotlight on the PROFILE study
SPICY-trial
ECCO 2024
Finally here: controlled trials in surgery!
VEGA-Study
ECCO 2024
Combination of different drug classes - risks and…
ECCO 2024
Treatment targets in 2024 - a silent revolution
ADMIRE-CD II, INSPIRE
ECCO 2024
Cell-based therapies: The end of the story or the…
VIVID-1
ECCO 2024
Mirikizumab in CD
COMMAND, INSPIRE
ECCO 2024
IL-23 in UC
VIVID-1, SEQUENCE
ECCO 2024
Ustekinumab first, anti-p19 second?
True North, PIZZICATO
ECCO 2024
Next chapter in S1P- and JAK-inhibition
ECCO 2024
Obefazimod & IL23R-CAR-Tregs - new molecules in focus
ECCO 2024
Tregs - a treatment for the future?
VIVID-1
ECCO 2024
Mirikizumab in crohn's disease
ADMIRE-CD II
ECCO 2024
Darvadstrocel for complex perianal fistulas and Crohn’s…
PIZZICATO
ECCO 2024
PIZZICATO - new JAKies for crohn's disease
VIVID-1
ECCO 2024
Mirikizumab in moderate to severe Crohn’s disease:…
PIZZICATO
ECCO 2024
Results of the phase II PIZZICATO (ritlecitinib &…
PROFILE
ECCO 2024
Changing the PROFILE of how we treat CD
VIVID-1
ECCO 2024
Mirikizumab vs Ustekinumab
VIVID-1
ECCO 2024
VIVID 1: Comparison of mirikizumab with ustekinumab in…
VIVID 1
ECCO 2024
VIVID 1: Mirikizumab in Crohn's Disease
VIVID-1
ECCO 2024
Mirikizumab bei Morbus Crohn
VIVID-1
ECCO 2024
VIVID 1- Comparação do Mirikizumab com o Ustecinumab na…
PIZZICATO
ECCO 2024
Resultaten van de fase 2 PIZZICATO (ritlecitinib &…
VIVID-1
ECCO 2024
Mirikizumab στη θεραπεία της μέτριας προς βαρειά NC:…
PIZZICATO
ECCO 2024
PIZZICATO - neue JAKs für Morbus Crohn
VIVID-1
ECCO 2024
Mirikizumab vs Ustekinumab
LUCENT-1 & -2
ECCO 2024
Mirikizumab in anti-TNF failures with UC
ECCO 2024
Long term outcome of Obefazimod in UC
COMMAND, QUASAR
ECCO 2024
Risankizumab & guselkumab in ulcerative colitis
ECCO 2024
VTX002 (S1P-modulator) & obefazimod in ulcerative…
CONFER project
ECCO 2024
The efficacy of biologics and small molecules in…
ECCO 2023
VTX-002 in patients with moderate to severe UC
ECCO 2024
VTX002 (S1P-Modulator) & Obefazimod bei Colitis…
COMMAND, QUASAR
ECCO 2024
Risankizumab & Guselkumab bei Colitis Ulcerosa
ECCO 2024
lange-termijns uitkomst van obefazimod in UC
ECCO 2024
VTX-002 in pazienti con colite ulcerosa da moderata a…
CONFER project
ECCO 2024
Leki biologiczne i małocząsteczkowe w terapii…
PROFILE, COMMAND SEQUENCE, VIVID-1
ECCO 2024
Therapy in transition
E-QUALITY
ECCO 2024
Still a long road ahead in standards of care in IBD –…
ECCO 2024
Comparability examination between SB17 and Ustekimumab…
PROFILE, COMMAND SEQUENCE, VIVID-1
ECCO 2024
Therapie im Umbruch
ECCO 2024
Esame di comparabilità tra SP17 e ustekimumab…
E-QUALITY
ECCO 2024
Marzenia a rzeczywistość – wyniki ankiety E-QUALITY na…
PROFILE
ECCO 2024
Changing treatment paradigm in CD
PROFILE
ECCO 2024
Results from the PROFILE-trial
ENEIDA registry of GETECCU
ECCO 2024
Biomarker for biological loss of response in CD?
ADMIRE-CD II
ECCO 2024
Allogenic mesenchymal stem cells for complex fistula in…
PROFILE
ECCO 2024
PROFILE: practice-changing results
PROFILE
ECCO 2024
Early intervention in Crohn´s disease therapy
PROFILE
ECCO 2024
PROFILE: Biomarkers not successfull for therapy…
ECCO 2024
Should we proactively treat CD-patients having small…
ADMIRE-CD II
ECCO 2024
Injection de cellules souches mesenchimateuses…
PROFILE
ECCO 2024
Cambiano i paradigmi di trattamento nelle malattie di…
ENEIDA registry of GETECCU
ECCO 2024
Biomarker for biological loss of response in CD?
PROFILE
ECCO 2024
Intervenção terapêutica precoce na doença de Crohn
ECCO 2024
Faut-il traiter les patients avec les lesions de Crohn…
PROFILE
ECCO 2024
Risultati dallo studio PROFILE
ECCO 2024
PROFILE: Biomarker nicht erfolgreich zur Prädiktion der…
VEGA-Study
ECCO 2024
Guselkumab & Golimumab have complementary effects when…
ACTIVE
ECCO 2024
Towards the proactive management of AS-UC responding to…
VEGA-Study
ECCO 2024
Guselkumab & Golimumab ont des effets complémentaires…
ACTIVE
ECCO 2024
Vers un traitement plus agressif de la colite aigüe…
ECCO 2024
Use of CAR-Tregs in IBD: preclinical data
ECCO 2024
Immunohomeostasis by regulatory CAR-T cells!?
PROFILE, COMMAND SEQUENCE, VIVID-1
ECCO 2024
Therapy in transition
ECCO 2024
Personalized treatment in IBD: reality or hype?
HELIOS trial
ECCO 2024
HD-WLE with segmental reinspection is not inferior to…
HELIOS trial
ECCO 2024
HD-WLE με επανεξέταση των τμημάτων δεν υπολείπεται της…
PROFILE, COMMAND SEQUENCE, VIVID-1
ECCO 2024
Therapie im Umbruch
ECCO 2024
gepersonaliseerde aanpak van IBD: realiteit of hype?
ECCO 2024
Utilizzo di cellule CAR Tregs nelle MICI: dati…
ECCO 2024
Immunohomöstase durch regulatorische CAR-T-Zellen!?
ECCO 2024
Implication of proctocolectomy in patients affected by…
International PSC Registry (IPSCR)
ECCO 2024
Colectomy and the natural history of PSC – lessons form…
Miracle-Project
ECCO 2024
MIRACLE project: Avoidance of protective Ileostomy
ADMIRE-CD II
ECCO 2024
Randomised clinical trials finally coming to IBD…
ECCO 2024
End of the Kono-S legend!
ECCO 2024
No changes to surgical techniques for ileosecal…
SPICY
ECCO 2024
Extended mesenterectomy is not superior to mesenteric…
ECCO 2024
Implicazioni della proctocolectomia in pazienti affetti…
ECCO 2024
La fin de la legende du Kono-S!
MIRACLE-Projekt
ECCO 2024
MIRACLE-Projekt: Verzicht auf protektive Ileostomie
SPICY
ECCO 2024
Η εκτεταμένη εκτομή του μεσεντερίου δεν υπερέχει της…
ADMIRE-CD II
ECCO 2024
Los ensayos clínicos aleatorizados llegan a la cirugía…
International PSC Registry (IPSCR)
ECCO 2024
Kolektomia a historia naturalna PSC – czy istnieje…
ECCO 2024
Molecular healing, our next goal?
ECCO 2024
Cicatrización molecular: nuestro próximo objetivo?
SELECTION
ECCO 2024
Transcriptomic profiles in patients with UC receiving…
ECCO 2024
Molecular effects of IL-23p19 blockade
ECCO 2024
Molekulare Effekte der IL-23p19-Blockade
SELECTION
ECCO 2024
Análise do Transcriptoma em doentes com colite ulcerosa…
ECCO 2024
Diet & Lifestyle: Keys for the management of IBD!
ECCO 2024
Diet & Lifestyle: Keys for the management of IBD!
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!